Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
about
Evolving Therapies and FAK Inhibitors for the Treatment of CancerTreatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinibDasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.Severe thrombocytopenia after dasatinib treatment in a patient with Philadelphia chromosome-positive chronic myeloid leukemia.Practical management of patients with chronic myeloid leukemia.Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.It's about time: lessons for solid tumors from chronic myelogenous leukemia therapyNovel dual Src/Abl inhibitors for hematologic and solid malignancies.Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaSuccessful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester.Chronic myelogenous leukemia: treatment and monitoring.Monitoring response and resistance to treatment in chronic myeloid leukemia.The role of dasatinib in the management of chronic myeloid leukemiaPilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemiaEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patientsDasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapyDasatinib-induced pleural effusion: Chylothorax, an option to consider.Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities.Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia.Dasatinib in chronic myeloid leukemia: a review.HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.Treatment of chronic myeloid leukemia when imatinib fails.Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.Evolution of therapies for chronic myelogenous leukemia.Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications.
P2860
Q28972291-54CEB907-D7A8-41D6-9BCA-413BD673AAF3Q33391185-7F39C93C-18A8-43D2-BC55-EFD49D93C1C2Q33397085-B0E91BB9-D490-4D9D-B637-39FA367D1FF4Q33399101-1FD2C94C-1748-4617-AEC3-A504C3E7B040Q33404602-B4A4598A-9464-4F0A-89AC-53EC5A0719EBQ33422727-D1F7490D-1A1F-4641-A1CF-0F4DAAF1BA54Q33849146-66C7D6B8-4A9E-4D87-BD93-D5F49063DAADQ33926222-A8C6D5B4-EF25-43AE-B452-04503E2DAA4CQ33936071-0718C4C9-ECD3-46E8-A16D-36ECB7998E74Q34121339-5ED8C565-E241-4FDC-A44A-B8BCEB0B8BF2Q34293414-B69AEA14-F793-4381-BC0E-67D1A11F1064Q34522789-24AD9619-6922-48B9-8C0F-2DC2C93CFEF1Q34523506-657AC23E-77AD-4AD1-97F8-17026F4C0F27Q34617628-B18D20CD-447D-4C87-8255-9E07CD60E2D9Q34761663-C0A613D2-E085-43E9-97B8-9C5060870D97Q35087994-04FF9642-B30D-43E9-B8A7-74205F7E4D46Q35510549-0DFE073A-3271-429A-AD95-D4B5A9E4C26CQ35569694-7E176A39-1F79-4423-8357-325D164670DBQ36462473-3908D0C6-5D91-41BE-B4C6-9E90CB1F5A92Q37026032-AAD9E3C7-4828-46BE-812D-02ABF27A9CC6Q37028631-25A7603D-081C-4E4E-A790-5AE2CCE30A86Q37139374-136BB31F-848B-4241-9890-E5C404DA73C4Q37194640-58CB4E49-F302-4769-96D5-8E6404C85683Q37295261-F5CDF17E-4AF3-4FF4-99C9-648D1E47CB47Q37350583-0B0C592A-9738-4AB2-BE21-0992814040EDQ37403226-110A41D2-4262-4A15-A025-BBAD67A602E1Q37428676-52E06D6D-C783-4E64-9AD8-874BC070E0B6Q37461942-CACED48B-029A-4445-9942-135DF7227FC6Q37475797-FED90224-66FA-4268-B58C-89633E9CC3C6Q37523302-DD929C3B-3DB0-4863-A1D9-9DB613C166F4Q37625289-93146C82-FD16-4CE9-ADF1-92BD87F8E9A6Q37657488-7CAA3D22-C50D-4188-9ED6-D15DA746206BQ37771246-C1026D04-BDC0-4DD7-BDD5-FB89D188DB15Q37781050-604B5139-B6E2-4EA5-AA16-2D29625D5A89Q37797981-937998C8-A858-4A85-B4A6-786BFED1430DQ37827875-013CFC82-2F48-494E-8033-D979F7C78F0AQ37853793-E83A64F3-527E-4E80-9600-084DACE31993Q37889508-AB8FCD3D-F4B4-4F1B-8BC0-647F32C01C9FQ37966915-DB2F31B3-972F-47A1-A109-AEDFA5485ECCQ37977471-3EE5A82F-D257-4605-9346-753CD3676BAD
P2860
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Efficacy and safety of dasatin ...... eloid leukemia in blast phase.
@ast
Efficacy and safety of dasatin ...... eloid leukemia in blast phase.
@en
Efficacy and safety of dasatin ...... eloid leukemia in blast phase.
@nl
type
label
Efficacy and safety of dasatin ...... eloid leukemia in blast phase.
@ast
Efficacy and safety of dasatin ...... eloid leukemia in blast phase.
@en
Efficacy and safety of dasatin ...... eloid leukemia in blast phase.
@nl
prefLabel
Efficacy and safety of dasatin ...... eloid leukemia in blast phase.
@ast
Efficacy and safety of dasatin ...... eloid leukemia in blast phase.
@en
Efficacy and safety of dasatin ...... eloid leukemia in blast phase.
@nl
P2093
P50
P921
P356
P1433
P1476
Efficacy and safety of dasatin ...... yeloid leukemia in blast phase
@en
P2093
G Martinelli
G Rege-Cambrin
H J Khoury
J M A Van Tornout
J P Radich
P2888
P304
P356
10.1038/LEU.2008.221
P577
2008-08-28T00:00:00Z
P5875
P6179
1023129448